Unknown PHASE3 INTERVENTIONAL 1-arm NCT02778711

Anti-IL-17 a New Treatment for Contact Dermatititis

Sponsor: Tanja Todberg, MD

Interventions secukinumab

Updated 6 times since 2017 Last updated: May 17, 2016 Started: Jan 31, 2016 Primary completion: Jun 30, 2017 Completion: Jun 30, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Allergic Contact Dermatitits and is currently ongoing. Tanja Todberg, MD leads this study, which shows 6 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE3

Status: Recruiting → Unknown Status
Feb 2017 — Jun 2018 [monthly]

Recruiting PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE3

First recorded

Jan 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tanja Todberg, MD

Data source: University of Copenhagen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hellerup, Denmark